BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 18940466)

  • 21. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.
    Masugata H; Senda S; Goda F; Yamagami A; Okuyama H; Kohno T; Hosomi N; Yukiiri K; Noma T; Murao K; Kohno M; Itoh S
    Tohoku J Exp Med; 2009 Mar; 217(3):169-74. PubMed ID: 19282651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Fabry Disease: Pathogenesis, Clinical Symptoms, and Treatment with Enzyme Replacement Therapy].
    Sawai S
    Brain Nerve; 2015 Sep; 67(9):1099-108. PubMed ID: 26329150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Daidone M; Miceli S; Pinto A
    Curr Pharm Des; 2020; 26(40):5089-5099. PubMed ID: 32183665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pain therapy for Fabry's disease].
    Sommer C; Uçeyler N; Duning T; Arning K; Baron R; Brand E; Canaan-Kühl S; Hilz M; Naleschinski D; Wanner C; Weidemann F
    Internist (Berl); 2013 Jan; 54(1):121-2, 124-30. PubMed ID: 23250563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease.
    Schiffmann R
    Pharmacol Ther; 2009 Apr; 122(1):65-77. PubMed ID: 19318041
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Changing Landscape of Fabry Disease.
    Svarstad E; Marti HP
    Clin J Am Soc Nephrol; 2020 Apr; 15(4):569-576. PubMed ID: 32132142
    [No Abstract]   [Full Text] [Related]  

  • 28. [Multisystem lesions in orphan diseases: rheumatological aspects of Fabry's disease. Case report].
    Mashkunova OV; Isabekova AH; Botabekova AZ; Novikov PI
    Ter Arkh; 2023 Aug; 95(6):505-510. PubMed ID: 38158971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Fabry's disease (alpha-galactosidase-A deficiency): recent therapeutic innovations].
    Germain DP
    J Soc Biol; 2002; 196(2):183-90. PubMed ID: 12360747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fabry's disease.
    Adam T; Alexandrescu L; Voinea F; Toringhibel M; Hâncu A
    Rom J Intern Med; 2006; 44(4):455-64. PubMed ID: 18386622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The prevalence of Fabry's disease among male patients on hemodialysis in Lithuania (a screening study)].
    Maslauskiene R; Bumblyte IA; Sileikiene E; Grazulis S; Laurinavicius A; Pleckaitis M; Alekniene D; Dobrovolskiene R; Vainauskas V; Juodeikiene L; Steckis R; Sakalauskiene M; Macius K; Urbanaviciene J; Labutiene V; Gaupsiene E; Ziaukiene G; Burbaickaja S; Gailiūnas J
    Medicina (Kaunas); 2007; 43 Suppl 1():77-80. PubMed ID: 17551281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.
    Spinelli L; Pisani A; Sabbatini M; Petretta M; Andreucci MV; Procaccini D; Lo Surdo N; Federico S; Cianciaruso B
    Clin Genet; 2004 Aug; 66(2):158-65. PubMed ID: 15253767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous complications of Anderson-Fabry disease.
    Giuseppe P; Daniele R; Rita BM
    Curr Pharm Des; 2013; 19(33):6031-6. PubMed ID: 23448454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastroenterological complications of Anderson-Fabry disease.
    Buda P; Książyk J; Tylki-Szymanska A
    Curr Pharm Des; 2013; 19(33):6009-13. PubMed ID: 23448457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fabry disease female proband with clinical manifestations similar to hypertrophic cardiomyopathy.
    Teragaki M; Tanaka A; Akioka K; Lan HT; Nishi Y; Yamano T; Yoshikawa J
    Jpn Heart J; 2004 Jul; 45(4):685-9. PubMed ID: 15353880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The heart in Fabry's disease.
    Sheppard MN
    Cardiovasc Pathol; 2011; 20(1):8-14. PubMed ID: 19919901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cardiac manifestations of Fabry's disease].
    Han ZH; Jiang TY; Ren XJ; Wu XS; Zhang WD; Chen F
    Zhonghua Nei Ke Za Zhi; 2009 Jun; 48(6):462-4. PubMed ID: 19954039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anderson-Fabry's disease: diagnostic problems, therapeutic relevance, and clinical experience in the treatment of the disease with enzyme replacement therapy in nephropathic patients].
    Cianciaruso B; Pisani A; Andreucci MV; Parente N; Andria G; Federico S; Sabbatini M; Sessa A
    G Ital Nefrol; 2003; 20(2):113-9. PubMed ID: 12746795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fabry's disease: diagnosis in the pediatric age group].
    Pintos Morell G
    An Esp Pediatr; 2002 Jul; 57(1):45-50. PubMed ID: 12139892
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
    Besson G; Vadot W; Guellerin J
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.